HERO Phase 3 trial

December 22, 2020December 22, 2020

FDA Approves Orgovyx, Oral ADT for Advanced Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix), an oral form of hormone therapy by Myovant Sciences, to treat adults with advanced prostate cancer. The approval, granted ... Read more

October 1, 2020October 1, 2020

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

News

Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for the ... Read more

December 4, 2019December 6, 2019

Relugolix Induces Sustained Testosterone Reduction in Advanced PC, HERO Phase 3 Trial Results Show

News

Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with ... Read more

November 14, 2018

Phase 3 Trial of Relugolix for Advanced Prostate Cancer Completes Patient Enrollment

News

A Phase 3 trial evaluating Myovant Sciences’ relugolix as a treatment for advanced prostate cancer patients who are sensitive to androgen deprivation treatments has completed patient enrollment, the company announced. The randomized ... Read more